158 related articles for article (PubMed ID: 23375828)
1. Iodine-125 seed implantation and deferred transurethral resection of the prostate for patients with lower urinary tract symptoms and localized prostate cancer.
Liu R; Luo F; Zhang Z; Xu Y
Clin Genitourin Cancer; 2013 Sep; 11(3):251-5. PubMed ID: 23375828
[TBL] [Abstract][Full Text] [Related]
2. Two-step transurethral surgery of the prostate and permanent implant brachytherapy for patients with lower urinary tract symptoms and low- to intermediate-risk prostate cancer.
Ivanowicz AN; Wakeman CM; Hubbard RT; DeVoe WB; Haake MR; Teigland CM
Brachytherapy; 2012; 11(6):483-8. PubMed ID: 21937283
[TBL] [Abstract][Full Text] [Related]
3. Modified transurethral resection of the prostate (TURP) for men with moderate lower urinary tract symptoms (LUTS) before brachytherapy is safe and feasible.
Brousil P; Hussain M; Lynch M; Laing RW; Langley SE
BJU Int; 2015 Apr; 115(4):580-6. PubMed ID: 24802744
[TBL] [Abstract][Full Text] [Related]
4. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.
Gutman S; Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath RW; Adamovich E
BJU Int; 2006 Jan; 97(1):62-8. PubMed ID: 16336330
[TBL] [Abstract][Full Text] [Related]
5. Prediction of genitourinary tract morbidity after brachytherapy for prostate adenocarcinoma.
Wehle MJ; Lisson SW; Buskirk SJ; Broderick GA; Young PR; Igel TC
Mayo Clin Proc; 2004 Mar; 79(3):314-7. PubMed ID: 15008604
[TBL] [Abstract][Full Text] [Related]
6. Re: iodine-125 seed implantation and deferred transurethral resection of the prostate for patients with lower urinary tract symptoms and localized prostate cancer.
Ivanowicz A; Haake M; Teigland C
Clin Genitourin Cancer; 2014 Apr; 12(2):e67. PubMed ID: 24388679
[No Abstract] [Full Text] [Related]
7. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy.
Kollmeier MA; Stock RG; Cesaretti J; Stone NN
J Urol; 2005 Mar; 173(3):808-12. PubMed ID: 15711274
[TBL] [Abstract][Full Text] [Related]
8. Risk of urinary incontinence following post-brachytherapy transurethral resection of the prostate and correlation with clinical and treatment parameters.
Mock S; Leapman M; Stock RG; Hall SJ; Stone NN
J Urol; 2013 Nov; 190(5):1805-10. PubMed ID: 23669568
[TBL] [Abstract][Full Text] [Related]
9. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
Mabjeesh NJ; Chen J; Stenger A; Matzkin H
Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of continence following 532 nm laser prostatectomy for patients previously treated with radiation therapy or brachytherapy.
No D; Osterberg EC; Otto B; Naftali I; Choi B
Lasers Surg Med; 2013 Aug; 45(6):358-61. PubMed ID: 23813669
[TBL] [Abstract][Full Text] [Related]
11. Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancer.
Tanaka N; Fujimoto K; Hirao Y; Asakawa I; Hasegawa M; Konishi N
Urology; 2009 Aug; 74(2):407-11. PubMed ID: 19376570
[TBL] [Abstract][Full Text] [Related]
12. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy.
Stone NN; Stock RG
Brachytherapy; 2003; 2(1):32-9. PubMed ID: 15062161
[TBL] [Abstract][Full Text] [Related]
13. The pathophysiology of lower urinary tract symptoms after brachytherapy for prostate cancer.
Blaivas JG; Weiss JP; Jones M
BJU Int; 2006 Dec; 98(6):1233-7; discussion 1237. PubMed ID: 17125481
[TBL] [Abstract][Full Text] [Related]
14. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.
Niehaus A; Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW; Adamovich E
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):136-43. PubMed ID: 16198062
[TBL] [Abstract][Full Text] [Related]
15. Dynamic dose-feedback prostate brachytherapy in patients with large prostates and/or planned transurethral surgery before implantation.
Acher PL; Popert R; Morris SL; Potters L; Austin-Smith SL; Johnson UH; Nichol JE; Beaney RP
BJU Int; 2007 May; 99(5):1066-71. PubMed ID: 17233801
[TBL] [Abstract][Full Text] [Related]
16. Segmental dosimetry, toxicity and long-term outcome in patients with prostate cancer treated with permanent seed implants.
Meyer A; Wassermann J; Warszawski-Baumann A; Baumann R; Machtens S; Karstens JH; Christiansen H; Merseburger A; Kuczyk MA; von Klot C
BJU Int; 2013 May; 111(6):897-904. PubMed ID: 23305079
[TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
[TBL] [Abstract][Full Text] [Related]
18. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.
Tsumura H; Satoh T; Ishiyama H; Tabata K; Kotani S; Minamida S; Kimura M; Fujita T; Matsumoto K; Kitano M; Hayakawa K; Baba S
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e385-92. PubMed ID: 21664068
[TBL] [Abstract][Full Text] [Related]
19. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation.
Lehrer S; Cesaretti J; Stone NN; Stock RG
BJU Int; 2006 Nov; 98(5):979-81. PubMed ID: 17034599
[TBL] [Abstract][Full Text] [Related]
20. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity.
Allen ZA; Merrick GS; Butler WM; Wallner KE; Kurko B; Anderson RL; Murray BC; Galbreath RW
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):981-7. PubMed ID: 15989998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
